Home » Regions » Global News » Kythera acquires ATX-101 rights from Bayer Consumer Care

Kythera acquires ATX-101 rights from Bayer Consumer Care

Thursday, March 13, 2014

Kythera Biopharmaceuticals has acquired all rights outside of the U.S. and Canada to ATX-101, a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat (double chin). In 2010, Kythera licensed the commercial rights to ATX-101 outside of the U.S. and Canada to Bayer Consumer Care.

“We are very pleased to acquire all rights to ATX-101 outside the U.S. and Canada, giving us full global rights to develop and commercialize ATX-101,” said Keith Leonard, Kythera’s president and CEO. “We appreciate Bayer’s investment in the ATX-101 global development program over the past four years. During that time we strengthened our financial position and assembled a senior executive team with global aesthetic development and commercialization expertise. I am confident in our ability to maximize the long-term global value of ATX-101.”

Bayer will receive $33 million in Kythera common stock, plus a $51 million note, payable no later than 2024. Bayer also is eligible to receive certain long-term sales milestone payments on annual sales outside of the U.S. and Canada.

For the past six years, ATX-101 has been the focus of a global clinical development program that has enrolled more than 2,500 patients worldwide, of which more than 1,600 have been treated with ATX-101. In addition, positive and consistent results from multiple phase III trials were reported in the U.S. and Europe, and will provide the basis for regulatory submissions for approval of ATX-101. Kythera plans to file a NDA for ATX-101 with the FDA in the second quarter of 2014. In addition, KYTHERA plans to make multiple ex-U.S. regulatory submissions in the next 12 months. If approved, ATX-101 will be a first-in-class submental contouring injectable drug. 

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!